Jazz Pharmaceuticals (JAZZ) Short term Debt (2010 - 2026)

Jazz Pharmaceuticals' Short term Debt history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• On a quarterly basis, Short term Debt rose 3224.19% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 3224.19% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, up 3222.26% from the prior year.
• Short term Debt steadied at $1.0 billion in Q1 2026 per JAZZ's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Short term Debt topped out at $1.0 billion in Q1 2026 and bottomed at $31.0 million in Q1 2022.
• The 5-year median for Short term Debt is $31.0 million (2022), against an average of $401.0 million.
• Across the five-year window, Short term Debt slumped 94.88% in 2025 and jumped 3224.19% in 2026, its largest moves.
• Year by year, Short term Debt stood at $31.0 million in 2022, then surged by 1851.46% to $605.0 million in 2023, then plunged by 94.88% to $31.0 million in 2024, then soared by 3222.26% to $1.0 billion in 2025, then grew by 0.06% to $1.0 billion in 2026.
• Per Business Quant, the three latest JAZZ Short term Debt figures stand at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025).